Is Axillary Dissection Mandatory Following a Positive Sentinel Node Biopsy?(Feature Article) (Report)
Advances in Oncology 2010, Dec, 5, 4
-
- £2.99
-
- £2.99
Publisher Description
Introduction Management of the axilla in breast cancer has evolved rapidly following the implementation of sentinel lymph node biopsy (SLNB). Histological examination of the sentinel node allows accurate prediction of the overall stage of the axilla in 97% of patients [1-5]. Following SLNB, approximately 25-30% of patients will be identified as having a positive biopsy [3,6,7].
GENRE
Health & Well-Being
RELEASED
2010
1 December
LANGUAGE
EN
English
LENGTH
34
Pages
PUBLISHER
Mediscript Ltd.
SIZE
250.4
KB
Therapeutic Mammoplasty: A Fusion of Oncological and Aesthetic Breast Surgery (Breast Cancer) (Report)
2010
American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Conference Report: Gastrointestinal Cancers)
2009
Sutent Satellite Symposium: Held Parallel to the 15th Annual Scientific Meeting of Alexandria Clinical Oncology Department (ACOD) Alexandria, Egypt, 14-16 April 2010: a Report from the Symposium (Conference Report: Renal Cell Carcinoma) (Report)
2010
The Future Is Brite (Feature Article) (Clinical Report)
2009
Aromatase Inhibitors and Evolution of the Lipid Profile (Clinical Report)
2009
Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma: A New Treatment Paradigm for Locally Advanced and Metastatic Disease in the Era of Targeted Therapy (Feature Article) (Clinical Report)
2010